-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $26

Benzinga·09/15/2026 13:41:32
Listen to the news
Mizuho analyst Graig Suvannavejh maintains Immix Biopharma (NASDAQ:IMMX) with a Outperform and raises the price target from $15 to $26.